Notable Stock Analysts Ratings Esperion Therapeutics, Inc. (ESPR)

Ebony Scott
March 20, 2017

Digging a bit further, company shares have been noted 9.16% off the 52 week high and 308.09% away from the 52 week low.

Top Ships Inc. (NASDAQ:TOPS) now has a High Price Target of $0.25.

Boasting a price of $23.67, Esperion Therapeutics (NASDAQ:ESPR) traded 52.64% higher on the day.

Many analysts are providing their Estimated Earnings analysis for Esperion Therapeutics, Inc. and for the current quarter 10 analysts have projected that the stock could give an Average Earnings estimate of $-1.42/share. (NASDAQ:ESPR) puts the stock on today's active list.

Some buy side analysts are also providing their Analysis on Esperion Therapeutics, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. 26,206,462 shares of the company were exchanged. Advisor Group Inc. increased its position in shares of Esperion Therapeutics by 0.6% in the third quarter. Over the past twelve months, Esperion Therapeutics, Inc.

Research Ratings: The Goldfield Corporation (GV), E*TRADE Financial Corporation (ETFC)
The stock is now moving above its 20-Day Simple Moving Average of -2.25% with the 50-Day Simple Moving Average of -2.25 percent. Roessner, EVP, sold 26,510 with an average share price of $21.24 per share and the total transaction amounting to $563,072.40.

USA intelligence chiefs to testify on Trump-Russia claims
The FBI director testified alongside National Security Agency head Michael Rogers before the House Intelligence Committee Monday. Trump recently made news on social media for accusing former President Obama of wiretapping Trump Tower during the campaign.

Defoe 'dreaming' of World Cup 2018 with England
When you come in as a youngster, you're like a sponge where you try to take everything from everyone. Playing in the major tournaments, going out and emulating the players you've seen on TV.

The company's stock now has 534 Million in market capitalization. Elkfork Partners LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at $169,000. The company has recorded a 50-day moving average of $23.80 and a 200-day moving average of $15.00. The Company's shares are trading 1.59% above their 50-day moving average and 17.08% above their 200-day moving average.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Wednesday, February 22nd. Finally, Dimensional Fund Advisors LP increased its position in shares of Esperion Therapeutics by 54.9% in the fourth quarter. Finally, Virginia Retirement Systems ET AL purchased a new position in Esperion Therapeutics during the third quarter worth about $242,000. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.24) by $0.05. (ESPR)'s shares have the potential to reach a high EPS of -1.27 per share, and a low EPS of -1.58 per share in the current quarter. Share performance for the month is now at 13.36%. During the same period in the prior year, the firm earned ($0.58) earnings per share.

Esperion Therapeutics, Inc is a lipid management company.

The Ann Arbor, Michigan-based company, which develops and commercializes treatments for LDL-C patients, plans to file a New Drug Application (NDA) with the FDA by the first quarter of 2019, subject to successful completion of an ongoing Phase 3 trial.

Other reports by GizPress

Discuss This Article